Translational Research in Oncology announced the first patient was randomized in the REPLACE (TRIO041) trial
Translational Research in Oncology shared on their LinkedIn page:
”TRIO is happy to announce that the first patient was randomized in the REPLACE (TRIO041) trial, a phase 3, randomized, multicenter, global clinical trial of regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC with beyond up-to-7 criteria.
REPLACE, a TRIO-sponsored trial supported by Bayer, is co-chaired by Peter Galle (University Medical Center Mainz, Germany) and Richard Finn (University of California Los Angeles, US). The goal of the trial is to test the hypothesis, in the phase 3 setting, that systemic therapy with regorafenib-pembrolizumab is advantageous over standard locoregional treatment in intermediate-stage HCC with high tumor burden.
TRIO is engaging its global investigator network to initiate sites across 13 countries. More information on the REPLACE (TRIO041) trial can be found here.”
-
Dec 10, 2023, 16:59 | InsightYüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 16:53 | PositiveMatteo Lambertini: December 7, 2023 …a day to remember
-
Dec 10, 2023, 12:45 | BlogSIOP: Worldwide Candle Lighting Day is a celebration of solidarity and memory
-
Dec 10, 2023, 12:20 | BlogTedros Adhanom Ghebreyesus: France plays a critical role in global health
-
Dec 10, 2023, 12:14 | BlogDinesh Pendharkar: More than 200000 women over two years
-
Dec 10, 2023, 05:08 | SocietiesGlobal Summit on War and Cancer: Agenda
-
Dec 10, 2023, 18:12The Cancer Research Interns (CRI) Summer Program is now accepting applications! - Train at NCI
-
Dec 10, 2023, 18:08Apply for the Basic Research in Cancer Health Disparities Program - NCI Center to Reduce Cancer Health Disparities (CRCHD)
-
Dec 10, 2023, 18:01Giselle Sholler: Our research that led to the FDA-Oncologic Drugs Advisory Committee 70% approval for moving Difluoromethylornithine forward
-
Dec 10, 2023, 16:59Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
-
Dec 10, 2023, 12:03Eleonora Teplinsky: The POSITIVE Trial SABCS23 updates are so important to help with oncofertility counseling
-
Dec 10, 2023, 16:53Matteo Lambertini: December 7, 2023 …a day to remember
-
Dec 8, 2023, 16:33Big thank you to Dr. Rucha Kiran Patil for sharing their experiences and learnings on writing abstracts and poster presentations - Novo Nordisk Haemophilia Foundation
-
Dec 6, 2023, 14:57Tracy Gosselin: Jennifer Petruno Receives DAISY Award for Extraordinary Nurses
-
Dec 3, 2023, 16:34Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
Dec 2, 2023, 18:08100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
Dec 10, 2023, 05:08Global Summit on War and Cancer: Agenda
-
Dec 4, 2023, 16:26SIOP 2023 by Numbers! - International Society of Paediatric Oncology
-
Dec 2, 2023, 16:43In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
Nov 28, 2023, 17:34The International Association of Cancer Registries annual conference - IARC
-
Nov 26, 2023, 18:05Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
Dec 10, 2023, 17:39Dr. Salami is the winner of the American Urological Association’s prestigious Gold Cystoscope Award - YUO
-
Dec 10, 2023, 17:26Mark Awad was honored by GO2 for Lung Cancer at the 18th Annual Simply the Best Gala - Dana-Farber Cancer Institute
-
Dec 9, 2023, 17:00Wafik S. El-Deiry: Honored to share the news of my election as the Chair of the WIN Consortium in Personalized Cancer Medicine
-
Dec 8, 2023, 17:54Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
-
Dec 8, 2023, 17:35Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity